http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
-
Phathom Pharmaceuticals (PHAT) Announces FDA Approval of VOQUEZNA Tablets
-
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
-
Phathom Pharma (PHAT) Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for Treatment of H. pylori Infection in Adults
-
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicill
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Phathom Pharmaceuticals (PHAT) Announces Vonoprazan NDA Submission for Non-Erosive GERD
-
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Phathom Pharmaceuticals (PHAT) Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
-
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
-
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
-
Phathom Pharmaceuticals (PHAT) Announces FDA Acceptance of NDA Resubmission for Erosive GERD
-
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Phathom Pharmaceuticals Inc. (PHAT) Resubmits Erosive GERD New Drug Application to FDA
-
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
-
Phathom Pharmaceuticals Reports First Quarter 2023 Results
-
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Phathom Pharmaceuticals (PHAT) Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
-
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
-
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
-
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
-
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
-
Phathom Pharma (PHAT) received complete response letters from FDA relating to its erosive esophagitis NDA and H. pylori post approval supplement
-
Phathom Pharmaceuticals Provides Regulatory Updates
-
Phathom Pharmaceuticals Provides Regulatory Updates
-
TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
-
Phathom Pharmaceuticals (PHAT) Reports Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial
-
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
-
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
-
Phathom Pharmaceuticals (PHAT) ) says FDA has notified it that no action will be taken on the NDA for vonoprazan on or prior to PDUFA date
-
Phathom Pharmaceuticals (PHAT) Provides Update on NDA for Vonoprazan
-
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
-
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
-
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
-
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
-
Phathom Pharmaceuticals (PHAT) Announces $40M Placement in Non-Dilutive Capital
-
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
-
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
-
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
-
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
-
Phathom Pharmaceuticals (PHAT) Reports Strong New Data of Vonoprazan
-
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (A
